Pharmacologic Vitreolysis in Vascular Diseases of the Retina

Abstract

Vascular diseases of the retina such as diabetic retinopathy and vascular occlusions account for a large proportion of visual morbidity and blindness worldwide. The role of vitreous in the pathogenesis of these conditions has been increasingly recognized. Despite advances in the surgical technique of pars plana vitrectomy, the use of intravitreal agents for the lysis of vitreous has received attention, guided largely by promising results from the trials involving patients with non-vascular retinal diseases such as vitreomacular traction. The purpose of this review is to provide a comprehensive summary of the present knowledge on pathophysiologic basis of pharmacologic vitreolysis and its efficacy in vascular diseases of the retina. A review of completed and ongoing clinical trials will be presented, along with insights into future directions of this therapy.

Biodistribution of adeno‐associated virus type 2 carrying multi‐characteristic opsin in dogs following intravitreal injection

“…To date, there are very few published studies of biodistribution following intravitreal injection of AAV2 14,54‐56 . A time course that spans the peak effect is desirable, with at least one dose that is above the intended clinical dose.…”

“…To date, there are very few published studies of biodistribution following intravitreal injection of AAV2. 14 , 54 , 55 , 56 A time course that spans the peak effect is desirable, with at least one dose that is above the intended clinical dose. It is preferable that a quantitative PCR assay be used for assessment of vector biodistribution and is validated using PCR as demonstrated in this paper.…”